Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01701141 · ClinicalTrials.gov registry record
Depression and Dopamine Transporter Function Study Using C-11 Altropane
A clinical trial of Major Depressive Disorder and Anhedonia, sponsored by Mclean Hospital.
- Completed
- Registry status
- 150
- Enrollment target
- 2
- Study locations
NCT01701141: Completed study of Major Depressive Disorder and Anhedonia, sponsored by Mclean Hospital.
NCT01701141 is a study of Major Depressive Disorder and Anhedonia that has completed, run by Mclean Hospital. The registered enrollment target is 150 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (60% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01701141, a study of Major Depressive Disorder and Anhedonia, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
Major depressive disorder (MDD) is often characterized by anhedonia and impaired ability to modulate behavior as a function of rewards. However, the neurobiology of anhedonia and reduced reward responsiveness remains largely unknown. Because dopamine (DA) plays a critical role in goal-directed behavior and reinforcement learning, DA dysregulation might play an important role. In fact, several lines of evidence suggest that down-regulation of DA transmission might characterize depression vulnerability and the emergence of depressive symptoms. The current study seeks to elucidate the role of DA dysfunction in MDD. We hypothesize that MDD subjects will show reduced DAT binding potential, reduced reward learning in the probabilistic reward task, and abnormal functional magnetic resonance imaging (fMRI) activation in dorsal and ventral striatal regions during an instrumental learning task. This study will include three sessions. The first will take place at Massachusetts General Hospital or at McLean Hospital's Center for Depression, Anxiety and Stress Research. The aims of this session will be to (a) explain the study; (b) collect written informed consent, and (c) assess the subject's eligibility. Following this, another session (either second or third in order) will take place at the MGH PET Imaging Laboratory. Participants will complete a PET scan and a probabilistic reward task designed to measure reward learning and sensitivity to reward. The radioactive tracer utilized is 11C-altropane. Another session (either second or third in order) will take place at the McLean Hospital Neuroimaging Center. Participants will complete an instrumental learning task while in the fMRI, followed by a social reinforcement learning task and an implicit learning serial reaction time task upon completion of the scan. In the instrumental learning task, participants have the opportunity to earn money but need to learn, by trial and error, stimulus-outcome associations. The social rein
Primary Outcome
11C-altropane binding is recording during the positron emission tomography (PET) scan and is used to measure dopamine transporter levels.
Conditions Studied
Study Locations (2)
Massachusetts
- McLean Hospital - Belmont
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-07 |
What the finished NCT01701141 record still lists
NCT01701141 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT01701141 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01701141 about?
NCT01701141 is a clinical study titled "Depression and Dopamine Transporter Function Study Using C-11 Altropane". Major depressive disorder (MDD) is often characterized by anhedonia and impaired ability to modulate behavior as a function of rewards. However, the neurobiology of anhedonia and reduced reward responsiveness remains largely unknown. Because dopamine (DA) plays a critical role in goal-directed behav...
What is the current status of trial NCT01701141?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2012-01. Estimated completion is 2014-07.
What conditions does trial NCT01701141 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Anhedonia.
Who is sponsoring clinical trial NCT01701141?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01701141 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01701141's enrollment target sits among peer trials
150 97th of 282 higher than 184 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Taking Action for College Students
RECRUITING · NA
-
Neural Response to Inflammatory Challenge in Major Depressive Disorder
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia